<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />



<title>Multitrial - methods for programs with several phase III trials</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>



<style type="text/css">
code {
white-space: pre;
}
.sourceCode {
overflow: visible;
}
</style>
<style type="text/css" data-origin="pandoc">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
{ counter-reset: source-line 0; }
pre.numberSource code > span
{ position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
{ content: counter(source-line);
position: relative; left: -1em; text-align: right; vertical-align: baseline;
border: none; display: inline-block;
-webkit-touch-callout: none; -webkit-user-select: none;
-khtml-user-select: none; -moz-user-select: none;
-ms-user-select: none; user-select: none;
padding: 0 4px; width: 4em;
color: #aaaaaa;
}
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa; padding-left: 4px; }
div.sourceCode
{ }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } 
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.at { color: #7d9029; } 
code span.bn { color: #40a070; } 
code span.bu { color: #008000; } 
code span.cf { color: #007020; font-weight: bold; } 
code span.ch { color: #4070a0; } 
code span.cn { color: #880000; } 
code span.co { color: #60a0b0; font-style: italic; } 
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.do { color: #ba2121; font-style: italic; } 
code span.dt { color: #902000; } 
code span.dv { color: #40a070; } 
code span.er { color: #ff0000; font-weight: bold; } 
code span.ex { } 
code span.fl { color: #40a070; } 
code span.fu { color: #06287e; } 
code span.im { color: #008000; font-weight: bold; } 
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.kw { color: #007020; font-weight: bold; } 
code span.op { color: #666666; } 
code span.ot { color: #007020; } 
code span.pp { color: #bc7a00; } 
code span.sc { color: #4070a0; } 
code span.ss { color: #bb6688; } 
code span.st { color: #4070a0; } 
code span.va { color: #19177c; } 
code span.vs { color: #4070a0; } 
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } 
</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    var j = 0;
    while (j < rules.length) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") {
        j++;
        continue;
      }
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') {
        j++;
        continue;
      }
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>




<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">Multitrial - methods for programs with
several phase III trials</h1>



<p>Suppose we are planning a drug development program testing the
superiority of an experimental treatment over a control treatment. Our
drug development program consists of an exploratory phase II trial which
is, in case of promising results, followed by a confirmatory phase III
trial.</p>
<p>The drugdevelopR package enables us to optimally plan such programs
using a utility-maximizing approach. To get a brief introduction, we
presented a very basic example on how the package works in <a href="https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html">Introduction
to planning phase II and phase III trials with drugdevelopR</a>.
Contrary to the basic setting, where only one phase III trial was
planned, we now want to show how to plan several phase III trials using
the package.</p>
<div id="the-example-setting" class="section level1">
<h1>The example setting</h1>
<p>Suppose we are developing a new tumor treatment, <em>exper</em>. The
patient variable that we want to investigate is how long the patient
survives without further progression of the disease (progression-free
survival). This is a time-to-event outcome variable. Therefore, we will
use the function <code>optimal_multitrial</code>, which calculates
optimal sample sizes and threshold decisions values for time-to-event
outcomes when several phase III trials are performed.</p>
<p>Within our drug development program, we will compare our experimental
treatment <em>exper</em> to the control treatment <em>contro</em>. The
treatment effect measure is given by <span class="math inline">\(\theta
= −\log(HR)\)</span>, where the hazard ratio <span class="math inline">\(HR\)</span> is the ratio of the hazard rates
between the two groups. If we assume that the hazard of experiencing a
progression is reduced by 75% in the treatment group compared to the
control group, we have a hazard ratio of 0.75.</p>
</div>
<div id="applying-the-package-to-the-example" class="section level1">
<h1>Applying the package to the example</h1>
<p>After installing the package according to the <a href="https://sterniii3.github.io/drugdevelopR/#Installation">installation
instructions</a>, we can load it using the following code:</p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" tabindex="-1"></a><span class="fu">library</span>(drugdevelopR)</span></code></pre></div>
<p>We insert the same input values as in the example for <a href="https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html">time-to-event
endpoints</a>. As in the basic setting, the treatment effect may be <a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html">fixed
or follow a prior distribution</a>. Furthermore, some <a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html">options
to adapt the program</a> to your specific needs are also available in
this setting, however skipping phase II, setting predefined benefit
categories and choosing different treatment effects in phase II and III
are not possible.</p>
<p>The package implements a framework developed for phase II/III drug
development programs where several phase III trials are performed. This
is of particular relevance as regulatory agencies often require
statistical significance in two or more phase III trials. Different
<em>cases</em>, defined by the number of significant trials needed for
approval, are possible. For each case, different <em>strategies</em> are
possible. They are defined by the number of phase III trials to be
conducted in order to reach the goal of the case. For the success of the
drug development program, it is necessary that the treatment effects of
all phase III trials point in the same direction. For example, if we
select case 3 and strategy 4, we require four phase III trials, where
three need to be significant at level <span class="math inline">\(\alpha\)</span> and the treatment effect of the
fourth must point in the same direction.</p>
<p>The following cases and possible strategies are implemented in the
package.</p>
<table>
<colgroup>
<col width="8%" />
<col width="91%" />
</colgroup>
<thead>
<tr class="header">
<th>Case</th>
<th>Possible strategies for this case</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1, 2</td>
</tr>
<tr class="even">
<td>2</td>
<td>1 (with significance level of <span class="math inline">\(\alpha^2\)</span>)* , 2, 3, 23*</td>
</tr>
<tr class="odd">
<td>3</td>
<td>1 (with significance level of <span class="math inline">\(\alpha^3\)</span>)*, 3, 4</td>
</tr>
</tbody>
</table>
<p>Note that setting <code>case = 1</code> and <code>strategy = 1</code>
would lead to the same results as in the basic setting. There are two
special strategies which we marked with a * in the table:</p>
<ul>
<li>When using strategy 23 (the “two+one” strategy) in case 2, two phase
III trials are conducted. If only one shows a significant positive
treatment effect (and the other trial’s treatment effect points at least
in the same direction), a third trial is conducted.</li>
<li>Setting <code>strategy = 1</code> in cases 2 and 3 leads to a
situation where one large phase III trial is conducted with adjusted
significance level, i.e. <span class="math inline">\(\alpha_{new} =
\alpha^2\)</span> in case 2 and <span class="math inline">\(\alpha_{new}
= \alpha^3\)</span> in case 3. This feature is implemented as there is
discussion that a larger trial with adjusted significance level may also
may serve evidence on efficacy (see Koch (2005)).</li>
</ul>
<p>So, in addition to the parameters from the basic setting, we provide
the following parameters:</p>
<ul>
<li>The parameter <code>case</code> allows us to chose the number of
trials in phase III that have to show a significant positive treatment
effect for the whole program to be deemed successful. In the following
example we set the parameter <code>case = 3</code>, indicating that at
least two trials in phase III have to show a significant treatment
effect in phase III.</li>
<li>The parameter <code>strategy</code> defines the number of trials
that are conducted in phase III. The strategies 1, 2, 3, and 4 (and 23)
are implemented. Setting <code>strategy = TRUE</code> returns the
results of the optimization for all implemented strategies for a
specific case. Note that not all strategies are implemented for each
case (see table above). For the following example we set
<code>strategy = TRUE</code>.</li>
</ul>
<p>Note that for the following example, some input parameters were
changed compared to the basic setting in order to reduce computation
time.</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" tabindex="-1"></a>res <span class="ot">&lt;-</span> <span class="fu">optimal_multitrial</span>(<span class="at">w =</span> <span class="fl">0.3</span>,                        <span class="co"># define parameters for prior</span></span>
<span id="cb2-2"><a href="#cb2-2" tabindex="-1"></a>   <span class="at">hr1 =</span> <span class="fl">0.7</span>, <span class="at">hr2 =</span> <span class="fl">0.8</span>, <span class="at">id1 =</span> <span class="dv">210</span>, <span class="at">id2 =</span> <span class="dv">420</span>,            <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span>
<span id="cb2-3"><a href="#cb2-3" tabindex="-1"></a>   <span class="at">d2min =</span> <span class="dv">20</span>, <span class="at">d2max =</span> <span class="dv">200</span>, <span class="at">stepd2 =</span> <span class="dv">5</span>,                   <span class="co"># define optimization set for d2</span></span>
<span id="cb2-4"><a href="#cb2-4" tabindex="-1"></a>   <span class="at">hrgomin =</span> <span class="fl">0.7</span>, <span class="at">hrgomax =</span> <span class="fl">0.9</span>, <span class="at">stephrgo =</span> <span class="fl">0.02</span>,         <span class="co"># define optimization set for HRgo</span></span>
<span id="cb2-5"><a href="#cb2-5" tabindex="-1"></a>   <span class="at">alpha =</span> <span class="fl">0.025</span>, <span class="at">beta =</span> <span class="fl">0.1</span>, <span class="at">xi2 =</span> <span class="fl">0.7</span>, <span class="at">xi3 =</span> <span class="fl">0.7</span>,       <span class="co"># drug development planning parameters</span></span>
<span id="cb2-6"><a href="#cb2-6" tabindex="-1"></a>   <span class="at">c2 =</span> <span class="fl">0.75</span>, <span class="at">c3 =</span> <span class="dv">1</span>, <span class="at">c02 =</span> <span class="dv">100</span>, <span class="at">c03 =</span> <span class="dv">150</span>,               <span class="co"># define fixed and variable costs</span></span>
<span id="cb2-7"><a href="#cb2-7" tabindex="-1"></a>   <span class="at">K =</span> <span class="cn">Inf</span>, <span class="at">N =</span> <span class="cn">Inf</span>, <span class="at">S =</span> <span class="sc">-</span><span class="cn">Inf</span>,                            <span class="co"># set constraints</span></span>
<span id="cb2-8"><a href="#cb2-8" tabindex="-1"></a>   <span class="at">b1 =</span> <span class="dv">1000</span>, <span class="at">b2 =</span> <span class="dv">2000</span>, <span class="at">b3 =</span> <span class="dv">3000</span>,                       <span class="co"># define expected benefits</span></span>
<span id="cb2-9"><a href="#cb2-9" tabindex="-1"></a>   <span class="at">fixed =</span> <span class="cn">TRUE</span>,                                          <span class="co"># choose if  effects are fixed or random</span></span>
<span id="cb2-10"><a href="#cb2-10" tabindex="-1"></a>   <span class="at">case =</span> <span class="dv">3</span>, <span class="at">strategy =</span> <span class="cn">TRUE</span>                              <span class="co"># choose case and strategy</span></span>
<span id="cb2-11"><a href="#cb2-11" tabindex="-1"></a>   <span class="at">num_cl =</span> <span class="dv">3</span>)</span></code></pre></div>
<div id="interpreting-the-output" class="section level2">
<h2>Interpreting the output</h2>
<p>After setting all these input parameters and running the function,
let’s take a look at the output of the program.</p>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" tabindex="-1"></a>res</span>
<span id="cb3-2"><a href="#cb3-2" tabindex="-1"></a><span class="co">#&gt; Optimization result with 3 significant trial(s) needed, strategy 1:</span></span>
<span id="cb3-3"><a href="#cb3-3" tabindex="-1"></a><span class="co">#&gt;  Utility: -231.07</span></span>
<span id="cb3-4"><a href="#cb3-4" tabindex="-1"></a><span class="co">#&gt;  Sample size:</span></span>
<span id="cb3-5"><a href="#cb3-5" tabindex="-1"></a><span class="co">#&gt;    phase II: 30, phase III: 368, total: 398</span></span>
<span id="cb3-6"><a href="#cb3-6" tabindex="-1"></a><span class="co">#&gt;  Expected number of events:</span></span>
<span id="cb3-7"><a href="#cb3-7" tabindex="-1"></a><span class="co">#&gt;    phase II: 20, phase III: 258, total: 278</span></span>
<span id="cb3-8"><a href="#cb3-8" tabindex="-1"></a><span class="co">#&gt;  Assumed event rate:</span></span>
<span id="cb3-9"><a href="#cb3-9" tabindex="-1"></a><span class="co">#&gt;    phase II: 0.7, phase III: 0.7</span></span>
<span id="cb3-10"><a href="#cb3-10" tabindex="-1"></a><span class="co">#&gt;  Probability to go to phase III: 0.57</span></span>
<span id="cb3-11"><a href="#cb3-11" tabindex="-1"></a><span class="co">#&gt;  Total cost:</span></span>
<span id="cb3-12"><a href="#cb3-12" tabindex="-1"></a><span class="co">#&gt;    phase II: 122, phase III: 454, cost constraint: Inf</span></span>
<span id="cb3-13"><a href="#cb3-13" tabindex="-1"></a><span class="co">#&gt;  Fixed cost:</span></span>
<span id="cb3-14"><a href="#cb3-14" tabindex="-1"></a><span class="co">#&gt;    phase II: 100, phase III: 150</span></span>
<span id="cb3-15"><a href="#cb3-15" tabindex="-1"></a><span class="co">#&gt;  Variable cost per patient:</span></span>
<span id="cb3-16"><a href="#cb3-16" tabindex="-1"></a><span class="co">#&gt;    phase II: 0.75, phase III: 1</span></span>
<span id="cb3-17"><a href="#cb3-17" tabindex="-1"></a><span class="co">#&gt;  Effect size categories (expected gains):</span></span>
<span id="cb3-18"><a href="#cb3-18" tabindex="-1"></a><span class="co">#&gt;   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000)</span></span>
<span id="cb3-19"><a href="#cb3-19" tabindex="-1"></a><span class="co">#&gt;  Success probability: 0.19</span></span>
<span id="cb3-20"><a href="#cb3-20" tabindex="-1"></a><span class="co">#&gt;  Success probability by effect size:</span></span>
<span id="cb3-21"><a href="#cb3-21" tabindex="-1"></a><span class="co">#&gt;    small: 0.06, medium: 0.11, large: 0.02</span></span>
<span id="cb3-22"><a href="#cb3-22" tabindex="-1"></a><span class="co">#&gt;  Significance level: 1.5625e-05</span></span>
<span id="cb3-23"><a href="#cb3-23" tabindex="-1"></a><span class="co">#&gt;  Targeted power: 0.9</span></span>
<span id="cb3-24"><a href="#cb3-24" tabindex="-1"></a><span class="co">#&gt;  Decision rule threshold: 0.76 [HRgo] </span></span>
<span id="cb3-25"><a href="#cb3-25" tabindex="-1"></a><span class="co">#&gt;  Assumed true effect: 0.7 [hr] </span></span>
<span id="cb3-26"><a href="#cb3-26" tabindex="-1"></a><span class="co">#&gt;  Treatment effect offset between phase II and III: 0 [gamma] </span></span>
<span id="cb3-27"><a href="#cb3-27" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb3-28"><a href="#cb3-28" tabindex="-1"></a><span class="co">#&gt; Optimization result with 3 significant trial(s) needed, strategy 3:</span></span>
<span id="cb3-29"><a href="#cb3-29" tabindex="-1"></a><span class="co">#&gt;  Utility: -411.1</span></span>
<span id="cb3-30"><a href="#cb3-30" tabindex="-1"></a><span class="co">#&gt;  Sample size:</span></span>
<span id="cb3-31"><a href="#cb3-31" tabindex="-1"></a><span class="co">#&gt;    phase II: 30, phase III: 258, total: 288</span></span>
<span id="cb3-32"><a href="#cb3-32" tabindex="-1"></a><span class="co">#&gt;  Expected number of events:</span></span>
<span id="cb3-33"><a href="#cb3-33" tabindex="-1"></a><span class="co">#&gt;    phase II: 20, phase III: 180, total: 200</span></span>
<span id="cb3-34"><a href="#cb3-34" tabindex="-1"></a><span class="co">#&gt;  Assumed event rate:</span></span>
<span id="cb3-35"><a href="#cb3-35" tabindex="-1"></a><span class="co">#&gt;    phase II: 0.7, phase III: 0.7</span></span>
<span id="cb3-36"><a href="#cb3-36" tabindex="-1"></a><span class="co">#&gt;  Probability to go to phase III: 0.5</span></span>
<span id="cb3-37"><a href="#cb3-37" tabindex="-1"></a><span class="co">#&gt;  Total cost:</span></span>
<span id="cb3-38"><a href="#cb3-38" tabindex="-1"></a><span class="co">#&gt;    phase II: 122, phase III: 483, cost constraint: Inf</span></span>
<span id="cb3-39"><a href="#cb3-39" tabindex="-1"></a><span class="co">#&gt;  Fixed cost:</span></span>
<span id="cb3-40"><a href="#cb3-40" tabindex="-1"></a><span class="co">#&gt;    phase II: 100, phase III: 150</span></span>
<span id="cb3-41"><a href="#cb3-41" tabindex="-1"></a><span class="co">#&gt;  Variable cost per patient:</span></span>
<span id="cb3-42"><a href="#cb3-42" tabindex="-1"></a><span class="co">#&gt;    phase II: 0.75, phase III: 1</span></span>
<span id="cb3-43"><a href="#cb3-43" tabindex="-1"></a><span class="co">#&gt;  Effect size categories (expected gains):</span></span>
<span id="cb3-44"><a href="#cb3-44" tabindex="-1"></a><span class="co">#&gt;   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000)</span></span>
<span id="cb3-45"><a href="#cb3-45" tabindex="-1"></a><span class="co">#&gt;  Success probability: 0.08</span></span>
<span id="cb3-46"><a href="#cb3-46" tabindex="-1"></a><span class="co">#&gt;  Success probability by effect size:</span></span>
<span id="cb3-47"><a href="#cb3-47" tabindex="-1"></a><span class="co">#&gt;    small: 0, medium: 0.05, large: 0.03</span></span>
<span id="cb3-48"><a href="#cb3-48" tabindex="-1"></a><span class="co">#&gt;  Significance level: 0.025</span></span>
<span id="cb3-49"><a href="#cb3-49" tabindex="-1"></a><span class="co">#&gt;  Targeted power: 0.9</span></span>
<span id="cb3-50"><a href="#cb3-50" tabindex="-1"></a><span class="co">#&gt;  Decision rule threshold: 0.7 [HRgo] </span></span>
<span id="cb3-51"><a href="#cb3-51" tabindex="-1"></a><span class="co">#&gt;  Assumed true effect: 0.7 [hr] </span></span>
<span id="cb3-52"><a href="#cb3-52" tabindex="-1"></a><span class="co">#&gt;  Treatment effect offset between phase II and III: 0 [gamma] </span></span>
<span id="cb3-53"><a href="#cb3-53" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb3-54"><a href="#cb3-54" tabindex="-1"></a><span class="co">#&gt; Optimization result with 3 significant trial(s) needed, strategy 4:</span></span>
<span id="cb3-55"><a href="#cb3-55" tabindex="-1"></a><span class="co">#&gt;  Utility: -436.79</span></span>
<span id="cb3-56"><a href="#cb3-56" tabindex="-1"></a><span class="co">#&gt;  Sample size:</span></span>
<span id="cb3-57"><a href="#cb3-57" tabindex="-1"></a><span class="co">#&gt;    phase II: 58, phase III: 416, total: 474</span></span>
<span id="cb3-58"><a href="#cb3-58" tabindex="-1"></a><span class="co">#&gt;  Expected number of events:</span></span>
<span id="cb3-59"><a href="#cb3-59" tabindex="-1"></a><span class="co">#&gt;    phase II: 40, phase III: 292, total: 332</span></span>
<span id="cb3-60"><a href="#cb3-60" tabindex="-1"></a><span class="co">#&gt;  Assumed event rate:</span></span>
<span id="cb3-61"><a href="#cb3-61" tabindex="-1"></a><span class="co">#&gt;    phase II: 0.7, phase III: 0.7</span></span>
<span id="cb3-62"><a href="#cb3-62" tabindex="-1"></a><span class="co">#&gt;  Probability to go to phase III: 0.5</span></span>
<span id="cb3-63"><a href="#cb3-63" tabindex="-1"></a><span class="co">#&gt;  Total cost:</span></span>
<span id="cb3-64"><a href="#cb3-64" tabindex="-1"></a><span class="co">#&gt;    phase II: 144, phase III: 716, cost constraint: Inf</span></span>
<span id="cb3-65"><a href="#cb3-65" tabindex="-1"></a><span class="co">#&gt;  Fixed cost:</span></span>
<span id="cb3-66"><a href="#cb3-66" tabindex="-1"></a><span class="co">#&gt;    phase II: 100, phase III: 150</span></span>
<span id="cb3-67"><a href="#cb3-67" tabindex="-1"></a><span class="co">#&gt;  Variable cost per patient:</span></span>
<span id="cb3-68"><a href="#cb3-68" tabindex="-1"></a><span class="co">#&gt;    phase II: 0.75, phase III: 1</span></span>
<span id="cb3-69"><a href="#cb3-69" tabindex="-1"></a><span class="co">#&gt;  Effect size categories (expected gains):</span></span>
<span id="cb3-70"><a href="#cb3-70" tabindex="-1"></a><span class="co">#&gt;   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000)</span></span>
<span id="cb3-71"><a href="#cb3-71" tabindex="-1"></a><span class="co">#&gt;  Success probability: 0.2</span></span>
<span id="cb3-72"><a href="#cb3-72" tabindex="-1"></a><span class="co">#&gt;  Success probability by effect size:</span></span>
<span id="cb3-73"><a href="#cb3-73" tabindex="-1"></a><span class="co">#&gt;    small: 0, medium: 0.17, large: 0.02</span></span>
<span id="cb3-74"><a href="#cb3-74" tabindex="-1"></a><span class="co">#&gt;  Significance level: 0.025</span></span>
<span id="cb3-75"><a href="#cb3-75" tabindex="-1"></a><span class="co">#&gt;  Targeted power: 0.9</span></span>
<span id="cb3-76"><a href="#cb3-76" tabindex="-1"></a><span class="co">#&gt;  Decision rule threshold: 0.7 [HRgo] </span></span>
<span id="cb3-77"><a href="#cb3-77" tabindex="-1"></a><span class="co">#&gt;  Assumed true effect: 0.7 [hr] </span></span>
<span id="cb3-78"><a href="#cb3-78" tabindex="-1"></a><span class="co">#&gt;  Treatment effect offset between phase II and III: 0 [gamma]</span></span></code></pre></div>
<p>The program returns a data frame where the output for all implemented
strategies is listed.</p>
<p>For strategy 1 we get:</p>
<ul>
<li><code>res[1,]$d2</code> is the optimal number of events for phase II
and <code>res[1,]$d3</code> the resulting number of events for phase
III. We see that the optimal scenario requires 20 events in phase II and
258 events in phase III, which correspond to 30 participants in phase II
and 368 in phase III.</li>
<li><code>res[1,]$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.76 in phase II in order to proceed to phase III.</li>
<li><code>res[1,]$u</code> is the expected utility of the program for
the optimal sample size and threshold value. In our case it amounts to
-231.07, i.e. we have an expected utility of -23 107 000$.</li>
<li>Note that the input parameter <code>alpha</code> is returned having
a value of 0.000016, which corresponds to the adjusted significance
level <span class="math inline">\(\alpha^3\)</span>.</li>
</ul>
<p>The results for strategy 3 are:</p>
<ul>
<li><code>res[2,]$d2</code> is the optimal number of events for phase II
and <code>res[2,]$d3</code> the resulting number of events for phase
III. We see that the optimal scenario requires 20 events in phase II and
180 events in phase III, which leads to 30 participants in phase II and
258 in phase III. This corresponds to three trials in phase III with
each trial having 86 participants.</li>
<li><code>res[2,]$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.7 in phase II in order to proceed to phase III.</li>
<li><code>res[2,]$u</code> is the expected utility of the program for
the optimal sample size and threshold value. In our case it amounts to
-411.1, i.e. we have an expected utility of -41 110 000$.</li>
</ul>
<p>Strategy 4 yields the following results:</p>
<ul>
<li><code>res[3,]$d2</code> is the optimal number of events for phase II
and <code>res[3,]$d3</code> the resulting number of events for phase
III. We see that the optimal scenario requires 40 events in phase II and
292 events in phase III, which leads to 58 participants in phase II and
416 in phase III. This corresponds to four trials in phase III with each
trial having 104 participants.</li>
<li><code>res[3,]$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.70 in phase II in order to proceed to phase III.</li>
<li><code>res[3,]$u</code> is the expected utility of the program for
the optimal sample size and threshold value. In our case it amounts to
-436.79, i.e. we have an expected utility of -43 679 000$.</li>
</ul>
</div>
</div>
<div id="where-to-go-from-here" class="section level1">
<h1>Where to go from here</h1>
<p>In this article we presented an example where several phase III
trials are conducted. Note that this example is not restricted to
time-to-event endpoints but can also be applied to binary and normally
distributed endpoints by using the functions
<code>optimal_multitrial_binary</code> and
<code>optimal_multitrial_normal</code>. For more information on how to
use the package, see:</p>
<ul>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html"><em>Introduction
to drugdevelopR:</em></a> See how the package works in a basic
example.</li>
<li><em>Different outcomes:</em> Apply it to <a href="https://sterniii3.github.io/drugdevelopR/articles/Binary_outcomes.html">binary
endpoints</a> and <a href="https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html">time-to-event
endpoints</a>.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html"><em>Interpreting
the rest of the output:</em></a> Obtain further details on your drug
development program.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html"><em>Fixed
or prior:</em></a> Model the assumed treatment effect on a prior
distribution.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>More
parameters:</em></a> Define custom effect size categories. Put
constraints on the optimization by defining maximum costs, the total
expected sample size of the program or the minimum expected probability
of a successful program. Define an expected difference in treatment
effect between phase II and III. Skip phase II.</li>
<li><em>Complex drug development programs:</em> Adapt to situations with
<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">biased
effect estimators</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html">multi-arm
trials</a>, or <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html">multiple
endpoints</a>.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html#parallel-computing"><em>Parallel
computing:</em></a> Be faster at calculating the optimum by using
parallel computing.</li>
</ul>
</div>
<div id="references" class="section level1">
<h1>References</h1>
<p>Koch, G. G. (2005). Statistical consideration of the strategy for
demonstrating clinical evidence of effectiveness one larger vs two
smaller pivotal studies by z. shun, e. chi, s. durrleman and l. fisher,
statistics in medicine 2005; 24: 1619–1637. Statistics in Medicine,
24(11):1639–1646.</p>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
